| Title |
Castration-resistant prostate cancer: potential targets and therapies
|
|---|---|
| Published in |
Biologics: Targets & Therapy, August 2012
|
| DOI | 10.2147/btt.s23954 |
| Pubmed ID | |
| Authors |
Aijaz Parray, Hifzur R Siddique, Sanjeev Nanda, Badrinath R Konety, Mohammad Saleem |
| Abstract |
The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 20% |
| Student > Doctoral Student | 3 | 12% |
| Student > Ph. D. Student | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Lecturer | 2 | 8% |
| Other | 4 | 16% |
| Unknown | 6 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 20% |
| Medicine and Dentistry | 5 | 20% |
| Agricultural and Biological Sciences | 3 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 7 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2012.
All research outputs
#20,972,772
of 25,759,158 outputs
Outputs from Biologics: Targets & Therapy
#228
of 286 outputs
Outputs of similar age
#140,878
of 179,852 outputs
Outputs of similar age from Biologics: Targets & Therapy
#12
of 12 outputs
Altmetric has tracked 25,759,158 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 286 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,852 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.